Comparison of abiraterone acetate and prednisolone (AAP) or combination enzalutamide (ENZ) plus AAP for metastatic hormone sensitive prostate cancer (mHSPC) starting androgen deprivation therapy (ADT): Overall survival (OS) results of 2 randomised phase III trials from the STAMPEDE protocol
Authors
Attard, G.Murphy, L.
Clarke, Noel W
Cross, W.
Gillessen, S.
Amos, C.
Brawley, C.
Jones, R.
Pezaro, C.
Malik, Z.
Montazeri, A.
Millman, R.
Cook, A.
Gilbert, D.
Langley, R.
Parker, C.
Sydes, M.
Brown, L.
Parmar, M.
James, N.
Affiliation
Research Department Of Oncology, UCL Cancer Institute - UCL - London's Global University, WC1 E6BT - London/GBIssue Date
2022
Metadata
Show full item recordCitation
Attard G, Murphy L, Clarke N, Cross W, Gillessen S, Amos C, et al. Comparison of abiraterone acetate and prednisolone (AAP) or combination enzalutamide (ENZ) plus AAP for metastatic hormone sensitive prostate cancer (mHSPC) starting androgen deprivation therapy (ADT): Overall survival (OS) results of 2 randomised phase III trials from the STAMPEDE protocol. Annals of Oncology. 2022 Sep;33(7):S1427-S8. PubMed PMID: WOS:000866211602475.Journal
Annals of OncologyDOI
10.1016/annonc/annonc1089Additional Links
https://dx.doi.org/10.1016/annonc/annonc1089Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/annonc/annonc1089